Issues related to corporate and international tax, including regarding Public Law 115-97, Tax Cuts and Jobs Act
Issues related to Puerto Rico
H.R. 7527 Medical Manufacturing, Economic Development, and Sustainability Act of 2020
H.R. 6443, Securing the National Supply Chain Act of 2020
H.R. 6930, Manufacturing API, Drugs, and Excipients (MADE) in America Act of 2020
Issues related to OECD negotiations on the taxation of global income S. 124 Preserve Access to Affordable Generics Act 
Issues related to drug patents and exclusivities (no bill)
H.R. 1520, Purple Book Continuity Act of 2019 
H.R. 1499, Protecting Consumer Access to Generic Drugs Act of 2019
S. 1224, The Stop STALLING Act
S. 1416, The Affordable Prescriptions for Patients Act
S.659 - the Biologics Patent Transparency Act
H.R. 938 Bringing Low-cost Options and Competition while Keeping Incentives for New Generics 
H.R. 5133 Affordable Prescriptions for Patients Through Promoting Competition 
H.R. 3991 Affordable Prescriptions for Patients Through Improvements to Patent Litigation Act
H.R. 2374 Stop Significant and Time-wasting Abuse Limiting Legitimate Innovation of New Generics Act
H.R. 2375 Preserve Access to Affordable Generics and Biosimilars Act Biosimilars, no specific bill 
Prescription drug value issues, no specific bill 
FDA issues, no specific bill 
Issues related to International Pricing Index (IPI), no specific bill
S. 657 Drug Price Transparency Act
S. 658 Accelerated Drug Approval for Prescription Therapies Act
S. 660 Efficiency and Transparency in Petitions Act
S. 1895, Lower Health Care Costs Act, a comprehensive bill designed to improve healthcare transparency and reduce healthcare costs, including prescription drugs
H.R. 1499, Protecting Consumer Access Generic Drugs Act
H.R. 1344, Competitive Deals Resulting in Unleashed Generics and Savings (DRUGS) Act
S. 1169, Ensuring Timely Access to Generics Act
S. 1617, Second Look at Drug Patents Act
H.R. 1520, Purple Book Continuity Act
S. 977, Transparent Drug Pricing Act 
S. 102, Prescription Drug Price Relief Act
S. 659, Biologic Patent Transparency Act
H.R. 1503, Orange Book Transparency Act
H.R. 2296, Fair Accountability and Innovative Research (FAIR) Drug Pricing Act
S. 1664, Prescription Drug Price Reporting Act
S.659 - the Biologics Patent Transparency Act
Supply Chain Issues, no specific bill H.R. 6800 - HEROES (Health and Economic Recovery Omnibus Emergency Solutions) Act and temporary access to Part B medicines at home
H.R. 8406 - The HEROES 2.0 (Health and Economic Recovery Omnibus Emergency Solutions) Act and temporary access to Part B medicines at home
H.R. 2693/S. 283 - Increasing Access to Osteoporosis Testing for Medicare Beneficiaries Act of 2019
2021 Notice of Benefit and Payment Parameters (NBPP) rule and cost-sharing assistance
H.R. 7647 - Preserving Patient Savings on Drug Costs Act
H.R. 6179 - Increasing Access to Biosimilars Act of 2020
Issues related to Most Favored Nation (MFN)/International Pricing Index (IPI) Executive Order, no specific bill
H.R. 4597/S. 3466 - the ACCESS for Biosimilars Act of 2020
H.R. 3 - Lower Prescription Drug Costs Now Act
H.R. 19/S. 3129 Lower Costs, More Cures Act
S. 2543 Prescription Drug Pricing Reduction Act
Issues related to the 340B program, no specific bill
Medicare Part B coverage and reimbursement issues
Home administration for Part B medicines due to COVID-19 
Issues related to International Pricing Index (IPI), no specific bill
Coding and reimbursement for biologics/biosimilars
Issues related to Part D redesign
Issues related to Part D rebate reform
Medicare Part D access issues for plan year 2020 and 2021, no specific bill
Issues related to Direct to Consumer Advertisement
Issues related to patient affordability issues, including copay cards, copay accumulators, National Benefit Payment Parameters
Medicare End Stage Renal Disease Prospective Payment System (ESRD PPS) Proposed Rule (bundled payment for calcimimetics)
Medicaid Value-Based Purchasing (VBP) Proposed Rule (Line Extensions & Manufacturer Co-pay Assistance)
TAX - Taxation/Internal Revenue Code CPT - Copyright/Patent/Trademark HCR - Health Issues MMM - Medicare/Medicaid
136 - Centers For Medicare and Medicaid Services (CMS) 24 - Commerce, Dept of (DOC) 11 - Executive Office of the President (EOP) 34 - Health & Human Services, Dept of (HHS) 2 - HOUSE OF REPRESENTATIVES 198 - Natl Economic Council (NEC) 18 - Office of Management & Budget (OMB) 1 - SENATE 136 - Centers For Medicare and Medicaid Services (CMS) 24 - Commerce, Dept of (DOC) 11 - Executive Office of the President (EOP) 34 - Health & Human Services, Dept of (HHS) 2 - HOUSE OF REPRESENTATIVES 198 - Natl Economic Council (NEC) 18 - Office of Management & Budget (OMB) 1 - SENATE 136 - Centers For Medicare and Medicaid Services (CMS) 24 - Commerce, Dept of (DOC) 11 - Executive Office of the President (EOP) 34 - Health & Human Services, Dept of (HHS) 2 - HOUSE OF REPRESENTATIVES 198 - Natl Economic Council (NEC) 18 - Office of Management & Budget (OMB) 1 - SENATE 136 - Centers For Medicare and Medicaid Services (CMS) 24 - Commerce, Dept of (DOC) 11 - Executive Office of the President (EOP) 34 - Health & Human Services, Dept of (HHS) 2 - HOUSE OF REPRESENTATIVES 198 - Natl Economic Council (NEC) 18 - Office of Management & Budget (OMB) 1 - SENATE
AMGEN, INC.
601 13th Street, NW, 11th Floor North, WASHINGTON, DC, 20005, US
L NICOLE CURRIE HELEN RHEE GREGORY PORTNER L NICOLE CURRIE WILLIAM O'BRIEN REBECCA MANDELL VICTORIA BLATTER HOWARD MOON JESSE KERNS JORDAN LYNN LAYSON WILLIAM O'BRIEN HELEN RHEE REBECCA MANDELL JESSE KERNS L NICOLE CURRIE GREGORY PORTNER VICTORIA BLATTER HOWARD MOON RUTH HOFFMAN JORDAN LYNN LAYSON L NICOLE CURRIE GREGORY PORTNER HELEN RHEE REBECCA MANDELL JESSE KERNS VICTORIA BLATTER WILLIAM O'BRIEN HOWARD MOON RUTH HOFFMAN JORDAN LYNN LAYSON